Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma

The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontline therapy (later amended to six months) and double-hit lymphoma were excluded. In this case report, we present the clinical course of an 85-year-old woman with primary refractory, double-hit DLBCL who was successfully treated with tafasitamab plus lenalidomide following disease progression on the R-mini-CHOP regimen. PEER REVIEWED ARTICLE **Peer reviewers:** Prof. Andreas Holbro, University Hospital Basel, Basel, Switzerland Prof. Christoph Renner, Hospital Hirslanden, Zurich, Switzerland Erik Aerts, Hematology Nurses & Healthcare Professionals Group, University Hospital Zurich, Zurich, Switzerland Received on January 09, 2025; accepted after peer review on March 20, 2025; published online on March 23, 2025.